Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 274

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper

Open access
Cristofanilli, Massimo, Pierga, Jean-Yves, Reuben, James, Rademaker, Alfred, Davis, Andrew A., Peeters, Dieter J., Fehm, Tanja, Nolé, Franco, Gisbert-Criado, Rafael, Mavroudis, Dimitrios, Grisanti, Salvatore, Giuliano, Mario, Garcia-Saenz, Jose A., Stebbing, Justin, Caldas, Carlos, Gazzaniga, Paola, Manso, Luis, Zamarchi, Rita, de Lascoiti, Angela Fernandez, De Mattos-Arruda, Leticia, Ignatiadis, Michail, Cabel, Luc, van Laere, Steven J., Meier-Stiegen, Franziska, Sandri, Maria-Teresa, Vidal-Martinez, Jose, Politaki, Eleni, Consoli, Francesca, Generali, Daniele, Cappelletti, Maria Rosa, Diaz-Rubio, Eduardo, Krell, Jonathan, Dawson, Sarah-Jane, Raimondi, Cristina, Rutten, Annemie, Janni, Wolfgang, Munzone, Elisabetta, Carañana, Vicente, Agelaki, Sofia, Almici, Camillo, Dirix, Luc, Solomayer, Erich-Franz, Zorzino, Laura, Darrigues, Lauren, Reis-Filho, Jorge S., Gerratana, Lorenzo, Michiels, Stefan, Bidard, François-Clément, Pantel, Klaus · 2019 · Critical Reviews in Oncology/Hematology

Abstract

BACKGROUND The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease. METHODS In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7.5 ml was used for stratification based on molecular subtypes, disease location, and prior treatments. Patients with ≥ 5 CTCs were classified as Stage IVaggressive, those with < 5 CTCs as Stage IVindolent. Survival was analyzed using Kaplan-Meier curves and the log rank test. RESULTS For all patients, Stage IVindolent patients had longer median overall survival than those with Stage IVaggressive (36.3 months vs. 16.0 months, P < 0.0001) and similarly for de novo MBC patients (41.4 months Stage IVindolent vs. 18.7 months Stage IVaggressive, p < 0.0001). Moreover, patients with Stage IVindolent disease had significantly longer overall survival across all disease subtypes compared to the aggressive cohort: hormone receptor-positive (44 months vs. 17.3 months, P < 0.0001), HER2-positive (36.7 months vs. 20.4 months, P < 0.0001), and triple negative (23.8 months vs. 9.0 months, P < 0.0001). Similar results were obtained regardless of prior treatment or disease location. CONCLUSIONS We confirm the identification of two subgroups of MBC, Stage IVindolent and Stage IVaggressive, independent of clinical and molecular variables. Thus, CTC count should be considered an important tool for staging of advanced disease and for disease stratification in prospective clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2018.12.004

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 274

Metadata

Authors
Cristofanilli, M., Pierga, J.-Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Giuliano, M., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., De Mattos-Arruda, L., Ignatiadis, M., Cabel, L., van Laere, S. J., Meier-Stiegen, F., Sandri, M.-T., Vidal-Martinez, J., Politaki, E., Consoli, F., Generali, D., Cappelletti, M. R., Diaz-Rubio, E., Krell, J., Dawson, S.-J., Raimondi, C., Rutten, A., Janni, W., Munzone, E., Carañana, V., Agelaki, S., Almici, C., Dirix, L., Solomayer, E.-F., Zorzino, L., Darrigues, L., Reis-Filho, J. S., Gerratana, L., Michiels, S., Bidard, F.-C., & Pantel, K.
Venue
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Published
2019-02
Volume
134
Pages
39-45
ISSN
1040-8428 (ISSN-L)
OpenAlex
W2905211300
Cited by
274
References
28
FWCI
8.13
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. https://app.cochat.ai/papers/10.1016/j.critrevonc.2018.12.004
The paper
Cristofanilli, M., Pierga, J.-Y., Reuben, J., Rademaker, A., Davis, A. A., Peeters, D. J., Fehm, T., Nolé, F., Gisbert-Criado, R., Mavroudis, D., Grisanti, S., Giuliano, M., Garcia-Saenz, J. A., Stebbing, J., Caldas, C., Gazzaniga, P., Manso, L., Zamarchi, R., de Lascoiti, A. F., . . . Pantel, K. (2019). The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2018.12.004

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.